AU2016301113B2 - Fibrotic treatment - Google Patents

Fibrotic treatment Download PDF

Info

Publication number
AU2016301113B2
AU2016301113B2 AU2016301113A AU2016301113A AU2016301113B2 AU 2016301113 B2 AU2016301113 B2 AU 2016301113B2 AU 2016301113 A AU2016301113 A AU 2016301113A AU 2016301113 A AU2016301113 A AU 2016301113A AU 2016301113 B2 AU2016301113 B2 AU 2016301113B2
Authority
AU
Australia
Prior art keywords
irap
fibrosis
optionally substituted
inhibitor
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016301113A
Other languages
English (en)
Other versions
AU2016301113A1 (en
Inventor
Siew Yeen Chai
Tracey Gaspari
Huey Wen LEE
Robert Widdop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monash University
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015903035A external-priority patent/AU2015903035A0/en
Application filed by Monash University filed Critical Monash University
Publication of AU2016301113A1 publication Critical patent/AU2016301113A1/en
Application granted granted Critical
Publication of AU2016301113B2 publication Critical patent/AU2016301113B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2016301113A 2015-07-30 2016-07-29 Fibrotic treatment Active AU2016301113B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015903035 2015-07-30
AU2015903035A AU2015903035A0 (en) 2015-07-30 Fibrotic treatment
PCT/AU2016/050681 WO2017015720A1 (en) 2015-07-30 2016-07-29 Fibrotic treatment

Publications (2)

Publication Number Publication Date
AU2016301113A1 AU2016301113A1 (en) 2018-02-22
AU2016301113B2 true AU2016301113B2 (en) 2019-10-03

Family

ID=57883919

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016301113A Active AU2016301113B2 (en) 2015-07-30 2016-07-29 Fibrotic treatment

Country Status (8)

Country Link
US (5) US10100311B2 (cg-RX-API-DMAC7.html)
EP (1) EP3328384B1 (cg-RX-API-DMAC7.html)
JP (3) JP2018527330A (cg-RX-API-DMAC7.html)
AU (1) AU2016301113B2 (cg-RX-API-DMAC7.html)
CA (1) CA3017028C (cg-RX-API-DMAC7.html)
HK (1) HK1256423A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201808478RA (cg-RX-API-DMAC7.html)
WO (1) WO2017015720A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3294721A4 (en) * 2015-05-08 2018-11-07 Monash University 4h-pyran compounds as insulin-regulated aminopeptidase (irap) inhibitors
EP3328384B1 (en) 2015-07-30 2020-07-29 Monash University Fibrotic treatment
US11331368B2 (en) * 2017-07-17 2022-05-17 Monash University Angiotensin receptor agonists and uses thereof
EP3902460A4 (en) * 2018-12-28 2023-01-11 The General Hospital Corporation ANTI-EPHRIN B2 BLOCKER ANTIBODIES FOR THE TREATMENT OF FIBROTIC DISEASES
WO2021050089A1 (en) * 2019-09-09 2021-03-18 Washington State University Genetic test for identifying cats at a high risk for developing tubulointerstitial fibrosis
CN115427060A (zh) 2020-02-19 2022-12-02 海必恩制药公司 环孢菌素类似物用于治疗纤维化的用途
JP2024543981A (ja) * 2021-12-01 2024-11-26 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 炎症性疾患の処置に使用するためのｉｒａｐアミノペプチダーゼ阻害剤の使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009065169A1 (en) * 2007-11-19 2009-05-28 Howard Florey Institute Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1789079T3 (da) * 2004-09-09 2013-03-11 Florey Howard Inst Insulinregulrede aminopeptidase (IRAP)-inhibitorer og anvendelser deraf
MX2008002431A (es) * 2005-08-23 2008-04-03 Wyeth Corp Metodos para el tratamiento contra ansiedad y para identificacion de agentes ansioliticos.
US20150057216A1 (en) * 2011-12-16 2015-02-26 Tarix Pharmaceuticals Ltd. Angiotensins for treatment of fibrosis
AU2013218148A1 (en) * 2012-02-06 2014-07-24 Glaxosmithkline Intellectual Property (No. 2) Limited PI3K inhibitors for treating fibrotic diseases
JP6327923B2 (ja) 2014-04-25 2018-05-23 旭化成株式会社 ポリアセタール樹脂組成物、及びそれからなる成形体
DE102014114090A1 (de) 2014-09-29 2016-03-31 Karlsruher Institut für Technologie Verfahren zur Abtrennung von Aluminium bei der Calciumsilikatproduktion
US9519061B2 (en) * 2014-12-26 2016-12-13 Here Global B.V. Geometric fingerprinting for localization of a device
EP3294721A4 (en) * 2015-05-08 2018-11-07 Monash University 4h-pyran compounds as insulin-regulated aminopeptidase (irap) inhibitors
EP3328384B1 (en) * 2015-07-30 2020-07-29 Monash University Fibrotic treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009065169A1 (en) * 2007-11-19 2009-05-28 Howard Florey Institute Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALBISTON, A.L. et al. "Identification and development of specific inhibitors for insulin-regulated aminopeptidase as a new class of cognitive enhancers" British Journal of Pharmacology (2011) Vol.164 pages 37 to 47 *
MA, L.-J. et al. "Role of Angiotensin II in Glomerular Injury" Seminars in Nephrology (2001) Vol.21 No.6 pages 544 to 553 *

Also Published As

Publication number Publication date
EP3328384A4 (en) 2019-03-06
JP7457360B2 (ja) 2024-03-28
SG11201808478RA (en) 2018-10-30
AU2016301113A1 (en) 2018-02-22
EP3328384B1 (en) 2020-07-29
CA3017028A1 (en) 2017-02-02
US20200362354A1 (en) 2020-11-19
US20210340547A1 (en) 2021-11-04
JP2018527330A (ja) 2018-09-20
US20180223287A1 (en) 2018-08-09
US20240084308A1 (en) 2024-03-14
US20190249179A1 (en) 2019-08-15
US10100311B2 (en) 2018-10-16
CA3017028C (en) 2020-06-16
HK1256423A1 (zh) 2019-09-20
EP3328384A1 (en) 2018-06-06
US11834663B2 (en) 2023-12-05
WO2017015720A1 (en) 2017-02-02
US11078488B2 (en) 2021-08-03
JP2020189845A (ja) 2020-11-26
US10787668B2 (en) 2020-09-29
JP2023030022A (ja) 2023-03-07

Similar Documents

Publication Publication Date Title
US11834663B2 (en) Fibrotic treatment
JP7050751B2 (ja) Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物
KR102347721B1 (ko) 섬유성 질환의 치료에 사용하기 위한 ppar 화합물
RU2694899C2 (ru) Производные пиридинкарбоксамида, способ их получения и их фармацевтическое применение
JP2012529432A (ja) アミノピロリジノン誘導体及びその使用
TW200948360A (en) Use of epothilone D in treating Tau-associated diseases including alzheimer's disease
AU2018392985A1 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
KR102661138B1 (ko) 치글리타자르 및 이의 관련 화합물의 용도
JP2003516327A (ja) アテローム性動脈硬化の予防および／または治療方法
KR20210097100A (ko) 2-(1-아실옥시-n-펜틸)벤조산 및 염기성 아미노산 또는 아미노구아니딘이 형성하는 염, 이의 제조 방법 및 용도
US12098138B2 (en) Substituted pyridinyl azetidinone derivatives for use in treating cancer and other diseases
BRPI0618939A2 (pt) método para modulação de sistema de proteìna quinase ativada por estresse
ES3002189T3 (en) Para-hydroquinone derivatives as vegf, tnf and/or il inhibitors for the treatment of neuroinflammatory diseases
WO2019117812A1 (en) Near infra-red molecular probes for use in diagnosis of fibrotic conditions and screening of anti-fibrotic drugs
CN111108083B (zh) 氨基亚甲基环己烷1,3-二酮化合物的用途
AU2016259977A1 (en) 4H-pyran compounds as insulin-regulated aminopeptidase (IRAP) inhibitors
ES2553862T3 (es) Formulaciones que comprenden compuestos de triptán
US10842794B2 (en) Use of Sigma-1 receptor agonist compounds
WO2021115141A1 (zh) 一种抑制HTT基因表达的siRNA及其前体和应用
US20220047550A1 (en) Compounds and methods for the treatment of degenerative disorders
WO2022141328A1 (zh) 硫代咪唑烷酮药物在治疗covid-19疾病中的用途
WO2025112034A1 (zh) 增强线粒体自噬的嵌合分子及其应用
EA046703B1 (ru) Ингибиторы киназы р38 снижают экспрессию dux4 и последующих генов для лечения fshd
EA046894B1 (ru) Ингибиторы rho-ассоциированной, содержащей суперспираль протеинкиназы
JP2014141472A (ja) １，３，５−トリアジン誘導体を有する線維化予防又は治療剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)